Phase 2 N=732 Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in the PANSS Total Score — 97.3; 97.1; 97.2; 96.7 Units on a scale — p=0.0005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=108 A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
Treatment Resistant Depressive Disorder
Primary: Panel A and B: Change From Baseline (Day 1) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Day 8- Analysis of Covariance (ANCOVA) Analysis — -4.9…
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Phase 2 N=204 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
Pruritus · Psoriasis
Primary: WI-NRS 4-point Responder Rate at Week 8 — 33.29; 21.07 % of subjects (incl. imputed data)
Phase 2 N=22 A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
Glioblastoma · Glioblastoma Multiforme
Primary: Median Overall Survival (OS) — 5.75 months
Phase 2 N=54 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Peanut Hypersensitivity · Food Hypersensitivity · Food Allergy
Primary: Population Sensitization Threshold in mg Peanut Protein Predicted to Provoke Reactions in 5% of the Peanut-allergic Population — 160; 300 mg
Phase 2 N=34 Safety and Efficacy of Eltrombopag at Escalated Doses
Immune Thrombocytopenia · Platelet Disorder
Primary: Number of Patients Responding to >75mg Daily as Defined by a Rise in Platelet Count by 20,000/Microliter, With a Total Platelet Count >50,000/Microliter, ON TWO…
Phase 2 N=260 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
Dengue Fever · Dengue Hemorrhagic Fever · Dengue Virus
Primary: Percentage of Participants With Antibody Titers of >= 10 1/Dilution (1/Dil) Against Each Dengue Virus Serotype Strain: CYD Vaccine 5555 and 5553 Formulation — 1.0; 3.0…
Phase 2 N=61 Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Neoplasm Malignant
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 16; 3; 35; 3 Participants
Phase 2 N=193 An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
Depressive Disorder, Major
Primary: Change From Baseline in Hamilton Depression Rating Scale (HDRS-17) Total Score at Week 12 — -10.6; -11.4 Units on a scale — p=0.310
Phase 2 N=334 Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
Diabetic Kidney Disease
Primary: Change in eGFR From Baseline at Week 48 — -2.83; -2.37; -4.07; -3.20 mL/min/1.73 m^2 — p=0.755
Phase 2 N=20 Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Primary Open Angle Glaucoma or Ocular Hypertension
Primary: Mean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility — 0.039; 0.007 mcl/min/mmHg — p=0.0010
Phase 2 N=40 A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration — 1.13; 1.59; 1.14; 4.74 fold change
Phase 2 N=2 TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
Choriocarcinoma
Primary: Progression Free Survival of Two Patients With Metastatic and Refractory Choriocarcinoma — 18 Months
Phase 2 N=24 A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Number of Participants With Adverse Events (Safety Profile) — 6; 13; 2; 11 Participants